In vitro inhibition of HUVECs by low dose methotrexate – insights into oral adverse events

Head & Face Medicine

Kai Wermker²  Cathrin Koiky¹  Johannes Kleinheinz¹  Thomas Szuwart¹  Tobias Annussek¹ 

[1] Department of Cranio-Maxillofacial Surgery, University Hospital of Muenster, Research Group Vascular Biology of Oral Structures (VABOS), Waldeyerstr.30, Muenster 48149, Germany;Department of Cranio-Maxillofacial Surgery, Fachklinik Hornheide at the Westphalian Wilhelms University of Muenster, Muenster, Germany

关键词: Wound healing;    In vitro;    Endothelial cells;    Methotrexate;    Antirheumatic drugs;    Oral health;   

Others  :  813379
DOI  :  10.1186/1746-160X-10-19

 received in 2013-12-18, accepted in 2014-05-12,  发布年份 2014

【 摘 要 】

Background

With socio-economic changes, dentists and maxillofacial surgeons are more and more faced with medically compromised patients. Especially, the admission of antirheumatic drugs has increased remarkably. So dentists and maxillofacial surgeons should be aware of related adverse reactions that affect the craniofacial region. To identify possible cellular effects of disease modifying antirheumatic drugs (DMARDs) we investigated the influence of methotrexate (MTX) on human umbilical vein endothelial cells (HUVECs).

Methods

HUVECs were incubated with various concentrations of MTX, corresponding to serum concentrations found in rheumatoid arthritis (RA) patients. The effect of MTX on cell proliferation, differentiation as well as mitochondrial activity was measured by use of immunostaining, cell counting and 3-(4, 5-dimethylthiazol-2-yl)- 2, 5-diphenyltetrazolium bromide (MTT) assay.

Results

All samples incubated with MTX (1-1000 nM) showed significantly decreased cell viability when compared to controls. Cells were less proliferating, but did not lose their ability to synthesize endothelial proteins. A slight dose dependency of inhibiting effects was demonstrated. The observed differences between control and sample groups were rising with longer duration.

Conclusion

Because of the crucial role of endothelial cells and their precursor cells in wound healing, a negative influence of MTX on oral health has to be supposed, correlating to clinical observations of adverse reactions in the oral cavity, such as ulcerative or erosive lesions.

【 授权许可】

   
2014 Annussek et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, Murray CJ: Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet 2013, 380(9859):2144-2162. doi:10.1016/S0140-6736(12)61690-0
• [2]Bornstein MM, Cionca N, Mombelli A: Systemic conditions and treatments as risks for implant therapy. Int J Oral Maxillofac Implants. 2009, 24(Suppl):12-27.
• [3]Guggenheimer J: Oral manifestations of drug therapy. Dent Clin North Am 2002, 46(4):857-868.
• [4]Scott DL, Wolfe F, Huizinga TW: Rheumatoid arthritis. Lancet 2010, 376(9746):1094-1108. doi:10.1016/S0140-6736(10)60826-4
• [5]Alamanos Y, Voulgari PV, Drosos AA: Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006, 36(3):182-188. Epub 2006 Oct 11
• [6]Jacobs JW: Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2012, 51(4):iv3-iv8. doi:10.1093/ rheumatology/kes083. Epub 2012 Apr 19
• [7]Visser K, Allaart CF, Huizinga TW: Use of methotrexate in undifferentiated arthritis. Clin Exp Rheumatol 2010, 28(61):S117-121. Epub 2010 Oct 28
• [8]Sokka T: Increases in use of methotrexate since the 1980s. Clin Exp Rheumatol 2010, 28(61):S13-20. Epub 2010 Oct 28
• [9]Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O‘Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64(5):625-639. doi:10.1002/acr.21641
• [10]Kruüger K, Wollenhaupt J, Albrecht K, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester G, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nuesslein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Mueller-Ladner U: German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm. Z Rheumatol 2012, 71(7):592-603.
• [11]Malaviya AN, Sharma A, Agarwal D, Kapoor S, Garg S, Sawhney S: Low-dose and high-dose methotrexate are two different drugs in practical terms. Int J Rheum Dis 2010, 13(4):288-293. doi:10.1111/j.1756-185X.2010.01564.x. Epub 2010 Aug 16
• [12]Yazici Y: Long-term safety of methotrexate in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2010, 28(61):S65-67. Epub 2010 Oct 28
• [13]Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford) 2007, 46(10):1520-1524.
• [14]Brinker RR, Ranganathan P: Methotrexate pharmacogenetics in rheumatoid arthritis. Clin Exp Rheumatol 2010, 28(61):S33-39. Epub 2010 Oct 28
• [15]Tian H, Cronstein BN: Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007, 65(3):168-173.
• [16]Carpenter EH, Plant MJ, Hassell AB, Shadforth MF, Fisher J, Clarke S, Hothersall TE, Dawes PT: Management of oral complications of diseasemodifying drugs in rheumatoid arthritis. Br J Rheumatol 1997, 36(4):473-478.
• [17]Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijsen MW, Laan RF: Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62(5):423-426.
• [18]Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999, 159(21):2542-2550.
• [19]Pedrazas CH, Azevedo MN, Torres SR: Oral events related to lo w-dose methotrexate in rheumatoid arthritis patients. Braz Oral Res 2010, 24(3):368-373.
• [20]Bissar L, Almoallim H, Albazli K, Alotaibi M, Alwafi S: Perioperative management of patients with rheumatic diseases. Open Rheumatol J 2013, 7:42-50. doi:10.2174/1874312901307010042. eCollection 2013
• [21]Szpaderska AM, Walsh CG, Steinberg MJ, DiPietro LA: Distinct patterns of angiogenesis in oral and skin wounds. J Dent Res 2005, 84(4):309-314.
• [22]Balaji S, King A, Crombleholme TM, Keswani SG: The Role of Endothelial Progenitor Cells in Postnatal Vasculogenesis: Implications for Therapeutic Neovascularization and Wound Healing. Adv Wound Care (New Rochelle) 2013, 2(6):283-295.
• [23]Kim KL, Song SH, Choi KS, Suh W: Cooperation of endothelial and smooth muscle cells derived from human induced pluripotent stem cells enhances neovascularization in dermal wounds. Tissue Eng Part A 2013, 19(21–22):2478-2485.
• [24]Wong VW, Crawford JD: Vasculogenic cytokines in wound healing. Biomed Res Int 2013, 2013:190486. doi:10.1155/2013/190486. Epub 2013 Feb 28
• [25]Hettler A, Werner S, Eick S, Laufer S, Weise F: A new in vitro model to study cellular responses after thermomechanical damage in monolayer cultures. PLoS One 2013, 8(12):e82635.
• [26]Lam HW, Lin HC, Lao SC, Gao JL, Hong SJ, Leong CW, Yue PY, Kwan YW, Leung AY, Wang YT, Lee SM: The angiogenic effects of Angelica sinensis extract on HUVEC in vitro and zebrafish in vivo. J Cell Biochem 2008, 103(1):195-211.
• [27]Jaffe EA: Culture of human endothelial cells. Transplant Proc 1980, 12(3 Suppl 1):49-53.
• [28]Leeb B, Dunky A, Ogris E, Wohanka A, Schenk G, Gaismayer K, Eberl R: Methotrexate serum-level determinations during low-dose therapy of rheumatoid and psoriatic arthritis. Int J Clin Pharmacol Res 1989, 9(3):209-215.
• [29]Pannecouque C, Daelemans D, De Clercq E: Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc 2008, 3(3):427-434. doi:10.1038/nprot.2007.517
• [30]Sandoval DM, Alarcón GS, Morgan SL: Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol. 1995, 34(Suppl 2):49-56.
• [31]Nikitakis NG, Brooks JK: Chronic ulcer in the hard palate. Methotrexate-induced oral ulceration. Gen Dent 2009, 57(1):89-92.
• [32]Kalantzis A, Marshman Z, Falconer DT, Morgan PR, Odell EW: Oral effects of lowdose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005, 100(1):52-62.
• [33]Troeltzsch M, von Blohn G, Kriegelstein S, Woodlock T, Gassling V, Berndt R, Troeltzsch M: Oral mucositis in patients receiving low-dose methotrexate therapy for rheumatoid arthritis: report of 2 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 2013, 115(5):e28-e33. doi:10.1016/j.oooo.2012.12.008
• [34]Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, Bombardier C, Wells GA, Tugwell P: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2013., 5CD000951. doi:10.1002/14651858.CD000951.pub2
• [35]Deschaumes C, Verneuil L, Ertault-Daneshpouy M, Adle-Biassette H, Galateau F, Aïnoun F, Micic-Polianski J, Janin A, Ameisen JC: CD95 ligand-dependant endothelial cell death initiates oral mucosa damage in a murine model of acute graft versus host disease. Lab Invest 2007, 87(5):417-429. Epub 2007 Mar 5
• [36]Bauer J, Fartasch M, Schuler G, Schell H: Ulcerative stomatitis as clinical clue to inadvertent methotrexate overdose. Hautarzt 1999, 50:670-673.
• [37]Schnabel A, Reinhold-Keller E, Willmann V, Gross WL: Side effects of 15 mg and 25 mg methotrexate/week for rheumatoid arthritis. Arthritis Rheum 1992, 5:146.
• [38]Zeng L, Yan Z, Ding S, Xu K, Wang L: Endothelial injury, an intriguing effect of methotrexate and cyclophosphamide during hematopoietic stem cell transplantation in mice. Transplant Proc 2008, 40(8):2670-2673. doi: 10.1016/j.transproceed.2008.06.038
• [39]Merkle CJ, Moore IM, Penton BS, Torres BJ, Cueny RK, Schaeffer RC Jr, Montgomery DW: Methotrexate causes apoptosis in postmitotic endothelial cells. Biol Res Nurs 2000, 2(1):5-14.
• [40]Cwikiel M, Eskilsson J, Albertsson M, Stavenow L: The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 1996, 7(7):731-737.
• [41]Yamasaki E, Soma Y, Kawa Y, Mizoguchi M: Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells. Br J Dermatol 2003, 149(1):30-38.
• [42]Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989, 32(9):1065-1073.
• [43]Tsukada T, Nakano T, Miyata T, Sasaki S: Life-Threatening Gastrointestinal Mucosal Necrosis during Methotrexate Treatment for Rheumatoid Arthritis. Case Rep Gastroenterol 2013, 7(3):470-475. doi:10.1159/000356817
• [44]Swift ME, Kleinman HK, DiPietro LA: Impaired wound repair and delayed angiogenesis in aged mice. Lab Invest 1999, 79(12):1479-1487.